Biundo Bruce
Professional Compounding Centers of America.
Int J Pharm Compd. 2023 Sep-Oct;27(5):358-360.
Between warnings from the U.S. Food and Drug Administration and many articles being published with the consensus that testosterone-replacement therapy had an increased cardiovascular risks in men, thereby questioning the relative safety of the therapy, the needs of hypogonadal (low testosterone) men, who also present with symptoms related to this condition, are much less likely to receive a treatment that can significantly improve their quality of life. This article discusses a major research project that determined that testosterone replacement therapy was no worse than a placebo in men with cardiovascular disease or at high risk for cardiovascular disease.
在美国食品药品监督管理局发出警告以及众多文章发表并达成共识,即睾酮替代疗法会增加男性心血管疾病风险,从而对该疗法的相对安全性提出质疑之后,性腺功能减退(睾酮水平低)且伴有与此病症相关症状的男性,接受能显著改善其生活质量治疗的可能性大大降低。本文讨论了一项重大研究项目,该项目确定睾酮替代疗法对患有心血管疾病或有心血管疾病高风险的男性来说,并不比安慰剂效果差。